Sign in

CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
813879991
Phone
617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Open-market sale President and CEO sold 716 shares at $10.59 ($7,582)
  2. DEFA14A Proxy Proxy Materials
  3. DEF 14A Proxy Proxy Statement
  4. 4 Open-market sale Chief Medical Officer sold 392 shares at $10.71 ($4,198)
  5. 4 Open-market sale Chief Financial Officer sold 398 shares at $10.71 ($4,263)
  6. 4 Open-market sale Chief Development Officer sold 238 shares at $10.71 ($2,549)
  7. 4 Open-market sale Chief Legal Officer sold 290 shares at $10.71 ($3,106)
  8. 4 Open-market sale Chief Financial Officer sold 318 shares at $10.22 ($3,250)
  9. 4 Open-market sale Chief Development Officer sold 176 shares at $10.22 ($1,799)
  10. 4 Open-market sale Chief Financial Officer sold 399 shares at $11.32 ($4,517)
  11. 4 Open-market sale Chief Medical Officer sold 390 shares at $11.32 ($4,415)
  12. 4 Open-market sale Chief Development Officer sold 238 shares at $11.32 ($2,694)
  13. 4 Open-market sale Chief Legal Officer sold 305 shares at $11.32 ($3,453)
  14. 4 Open-market sale President and CEO sold 706 shares at $10.51 ($7,420)
  15. CORRESP Other Correspondence Between Filers and SEC Staff
  16. CORRESP Other Correspondence Between Filers and SEC Staff
  17. UPLOAD Other SEC-generated Letter
  18. S-8 Other Securities Offered to Employees in Benefit Plans
  19. S-8 Other Securities Offered to Employees in Benefit Plans
  20. S-3 Offering Registration Statement

Page 14 of 24 · 471 filings